TRIBUNNEWS.COM, MOSCOW – The world’s first study of a combination of AstraZeneca’s coronavirus (Covid-19) vaccine and the first component of Russia’s Sputnik-V vaccine, conducted in Azerbaijan, showed no serious side effects or Covid-19 infection after vaccination.
The statement was made by the Russian Direct Investment Fund (RDIF) on Friday local time.
“Studies on the safety and immunogenicity of the combination of the AstraZeneca vaccine and the first component of the Sputnik V vaccine in Azerbaijan began in February 2021,” the RDIF said in a statement.
To date, 50 volunteers have been vaccinated and new participants have been invited to take part in the trial.
“An interim analysis of the data shows a high safety profile for the combined use of the vaccine ‘without serious side effects or cases of coronavirus after vaccination’,” explains RDIF.
Quoted from the page Sputnik News, Friday (30/7/2021), preliminary data on the immunogenicity of the combined use of the vaccine in Azerbaijan will be published in August.
“We hope this will be a success in Azerbaijan and other countries, as it will enable the implementation of a more effective vaccination program and protect more people around the world,” said RDIF.
RDIF CEO Kirill Dmitriev said that research to determine the effectiveness of the AstraZeneca and Sputnik V vaccines was needed to determine how effective the combination of the Covid-19 vaccine was.
“We consider it important to conduct joint research on the combination of the first component of Sputnik V with vaccines from other manufacturers for a more effective fight against the emerging new variant of Covid-19,” said Dmitriev.
On the other hand, AstraZeneca’s General Manager in Russia and Eurasia, Irina Panarina said that the heterogeneous major improvement involving administering different vaccine components to patients was one of the ‘most promising vaccination regimens’ to study.
“This is especially relevant now, when many countries are facing problems with preventing the spread of new variants and the need for additional population (booster) vaccinations is also increasing. That’s why the results of the study can be very important for countries using AstraZeneca and Sputnik V vaccines, ‘ said Panarina.
It should be noted that Sputnik Light is the first component version of the Russian Covid-19 vaccine ‘Sputnik-V’ developed by RDIF and the Gamaleya Institute.
According to the RDIF, Sputnik Light has shown up to 79.4 percent effectiveness against Covid-19, higher than some other two-dose vaccines.
While AstraZeneca is a vaccine developed by the University of Oxford and AstraZeneca.
According to data published in the Lancet, at the first dose, the vaccine was 76.0 percent effective against the coronavirus, then 81.3 percent after the second dose.
–
